Pharma Focus Asia
KP - Sustainable Packaging Solutions

Pharmaron Invests US$189.79 million (£151 million) to Open New Manufacturing Facility in UK

Introduction:

Pharmaron plans to open a new gene production facility to expand its viral vector and DNA manufacturing facilities to more than 8,000 square metres.

Features:

The new facility covers an area of 3,500 sqM for future commercial scale GMP capacity.

This expansion project includes a quadrupling of gene therapy process development and analysis capabilities, which include viral vector, DNA and RNA drug product formulation.

The facility will significantly increase the range of  services offered to vaccine, cell and gene therapy customers and enables to continue expand its research team in Liverpool.

The expansion will allow to continue beyond the capacity of the current state-of-the-art development and manufacturing practise facility, which will be fully operational during and after the expansion project.

The new facility is expected to begin in January 2023 and fully be operational in 2024.

Specifications:

Name         Pharmaron
Type           New Construction
Budget        US$189.79 million (£151 million)
Year            2024

Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024Equinix accelerated medical research...CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?